Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 9/20 | 0.40 |
| ▸ | JAK2 | O60674 | 7/20 | 0.40 |
| ▸ | JAK1 | P23458 | 7/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 7/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 7/20 | 0.38 |
| ▸ | TAS1R2 | Q8TE23 | 7/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1369381 | 0.86 | JAK3 (0.56) | JAK3JAK2JAK1 | |
| SCHEMBL15755604 | 0.81 | AKT1 (0.39) | HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL15755603 | 0.81 | AKT1 (0.39) | HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL14795085 | 0.81 | JAK3 (0.48) | JAK3JAK2JAK1KDM4E | |
| SCHEMBL14795091 | 0.81 | DYRK1A (0.42) | JAK3JAK2JAK1HPGDKDM4E | |
| SCHEMBL15755400 | 0.80 | TDP1 (0.41) | JAK3JAK2JAK1HPGDKDM4E | |
| SCHEMBL14795121 | 0.80 | JAK3 (0.51) | JAK3JAK2JAK1 | |
| SCHEMBL14795087 | 0.79 | JAK3 (0.41) | JAK3JAK2JAK1ALDH1A1 | |
| SCHEMBL14795191 | 0.79 | JAK3 (0.39) | JAK3JAK2JAK1 | |
| SCHEMBL15755925 | 0.79 | JAK3 (0.58) | JAK3JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155376-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2014-06-05 | — | — | US | claimed |
| US-20140155376-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2571880-A1 | PYRROLO [2, 3 - B]PYRAZINE - 7 - CARBOXAMIDE DERIVATIVES AND THEIR USE AS JAK AND SYK INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155376-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | SYK, ZAP70, JAK2 | JAK3 7/4885JAK2 3/4885JAK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.